Beginners’ Portfolio: What Have Vodafone Group plc, GlaxoSmithKline plc And Barclays PLC Done For Our Blue-Chip Prospects?

How did blue-chip purchases of Vodafone Group plc (LON: VOD), GlaxoSmithKline plc (LON: GSK) and Barclays PLC (LON: BARC) pan out?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

This article is the latest in a series that aims to help novice investors with the stock market. To enjoy past articles in the series, please visit our full archive.

The Beginners’ Portfolio is a virtual portfolio, run as if based on real money with all costs, spreads and dividends accounted for. Transactions made for the portfolio are for educational purposes only and do not constitute advice to buy or sell.

When I started the Beginners’ Portfolio my intention was to go for a combination of blue-chip dividend-paying shares and growth shares, and the success so far has been mixed with both approaches. Today I’m going to look at the blue-chip portion of the portfolio, paying special attention to one share I’ve since sold and two I still keep.

Telecoms profit

I sold Vodafone (LSE: VOD) back in December 2013 at a price of 234p, mainly because I thought its undervaluation was out by then, and partly because voice revenues were falling and I didn’t see a clear forward strategy for the company. As it happened, the timing worked out pretty well, and the portfolio made a capital gain of £166.46 with dividends of £58.35 added to the pot — a very nice overall gain of 45% over a 19-month period, after accounting for all costs.

Since then the price has been erratic and today is a little higher at 244p, but I think I made the right decision at the time.

Pharma laggard

GlaxoSmithKline (LSE: GSK) has not worked out as well as I thought it would have by now since I bought it in June 2012. In fact, if I sold at today’s 1,409p level I’d realise a loss on the share price of 6.6% — although total dividends of £79.56 would swing that to a modest total 9.2% gain after costs.

I thought the prospects of a return to earnings growth in 2016 would have improved sentiment towards Glaxo by now, but until that happens I’m happy to hold and keep taking dividend yields of around 6%.

Banking on banking

As the banking sector returned to health, I decided I wanted one to help give us a balanced portfolio, and I went for Barclays (LSE: BARC) in February 2014. Since then we’ve enjoyed a 6.7% gain (after costs) from a share price rise to 282p, with £15.75 in dividends taking the total gain to 9.6%.

One of my big reasons for choosing Barclays was its recovering dividend. It only yielded 2.7% in 2014 but it was very well covered. And we have EPS growth of around 33% forecast for this year, followed by another 20% in 2016, which makes me think we’re still in early days of Barclays’ recovery — and it was a good time to get in.

Bottom line

How has the blue-chip portion of the portfolio performed overall? I couldn’t finish without mentioning the overall 18% loss I took when I dumped Tesco, eased a little by some dividends in the early days. BP has been pretty flat with a total return of 2.8%, Rio Tinto is disappointingly down 13%, again softened by decent dividends, BAE Systems is sitting pretty with a very nice 54% overall gain, and Aviva has given us an even better 74% gain so far.

The blue-chip portion of the portfolio is up 16% after considering the effects of all costs (including the cost of selling the whole lot today). For an average holding time of around a couple of years, that compares reasonably well to the 10% or so we’d have gained from a FTSE 100 tracker over a similar period.

Next time I’ll take a look at the portfolio’s growth stocks.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended Barclays and GlaxoSmithKline, and owns shares in Tesco. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

A senior man and his wife holding hands walking up a hill on a footpath looking away from the camera at the view. The fishing village of Polperro is behind them.
Investing Articles

Here’s how a £20k ISA could generate £7,875 in monthly passive income

Have £20,000 ready to invest? Royston Wild explains how you could put this in a Stocks and Shares ISA to…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

By April 2027, £2,630 invested in Barclays shares could be worth…

Barclays shares have been flying. But what might happen to a chunk of money invested in the bank's stock over…

Read more »

Satellite on planet background
Investing Articles

MTI Wireless Edge: the 61p defence penny stock that’s delivered 10x the return of Rolls-Royce shares in 2026

Edward Sheldon has spotted a penny stock in the defence space that offers growth, value, dividend income, and share price…

Read more »

Happy woman commuting on a train and checking her mobile phone while using headphones
Investing For Beginners

Is this the biggest bargain in the FTSE 100 right now?

Jon Smith reviews a FTSE 100 stock that's fallen by 18% so far this year that he believes could be…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Will Rolls-Royce shares soar to £17.40 or sink to 900p?

Rolls-Royce shares have surged almost 90% in value over the last 12 months. Can the FTSE 100 company repeat the…

Read more »

A quiet morning and an empty Victoria Street in Edinburgh's historic Old Town.
Investing Articles

£10,000 invested in Scottish Mortgage shares 5 weeks ago is now worth…

Why have Scottish Mortgage shares displayed resilience in the FTSE 100 index since the war in Iran started a few…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

How can I target £14,132 a year in dividend income from a £20,000 holding in this FTSE 250 dividend gem?

This FTSE 250 dividend heavyweight keeps generating market-beating yields, with forecasts of more to come as earnings momentum continues to…

Read more »

Nottingham Giltbrook Exterior
Investing Articles

Marks and Spencer’s share price is down 16% to below £4! Is now the time for me to buy the dip with an eye to £8+?

Marks and Spencer’s share price has dipped, but is the market missing a far bigger story? The latest numbers hint…

Read more »